A citation-based method for searching scientific literature

Benjamin J Chen, Bjoern Chapuy, Jing Ouyang, Heather H Sun, Margaretha G M Roemer, Mina L Xu, Hongbo Yu, Christopher D M Fletcher, Gordon J Freeman, Margaret A Shipp, Scott J Rodig. Clin Cancer Res 2013
Times Cited: 528







List of co-cited articles
892 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman,[...]. N Engl J Med 2015
32

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Junichi Kiyasu, Hiroaki Miyoshi, Akie Hirata, Fumiko Arakawa, Ayako Ichikawa, Daisuke Niino, Yasuo Sugita, Yuji Yufu, Ilseung Choi, Yasunobu Abe,[...]. Blood 2015
282
29

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Margaretha G M Roemer, Ranjana H Advani, Azra H Ligon, Yasodha Natkunam, Robert A Redd, Heather Homer, Courtney F Connelly, Heather H Sun, Sarah E Daadi, Gordon J Freeman,[...]. J Clin Oncol 2016
404
26

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Martin Gutierrez, Michael M Millenson, Adam D Cohen, Stephen J Schuster, Daniel Lebovic,[...]. J Clin Oncol 2016
591
26

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, Scott J Rodig, Przemyslaw Juszczynski, Treeve Currie, Evan O'Donnell, Bjoern Chapuy, Kunihiko Takeyama, Donna Neuberg, Todd R Golub,[...]. Blood 2010
757
25

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
Michael R Green, Scott Rodig, Przemyslaw Juszczynski, Jing Ouyang, Papiya Sinha, Evan O'Donnell, Donna Neuberg, Margaret A Shipp. Clin Cancer Res 2012
420
24

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen S Snyder, Alejandro D Ricart, Arun Balakumaran, Shelonitda Rose,[...]. J Clin Oncol 2016
415
21

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy,[...]. J Clin Oncol 2019
124
20

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
David J Andorsky, Reiko E Yamada, Jonathan Said, Geraldine S Pinkus, David J Betting, John M Timmerman. Clin Cancer Res 2011
248
18

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Dohee Kwon, Sehui Kim, Pil-Jong Kim, Heounjeong Go, Soo Jeong Nam, Jin Ho Paik, Young A Kim, Tae Min Kim, Dae Seog Heo, Chul Woo Kim,[...]. Histopathology 2016
101
17

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos,[...]. J Clin Oncol 2017
528
17

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Anas Younes, Armando Santoro, Margaret Shipp, Pier Luigi Zinzani, John M Timmerman, Stephen Ansell, Philippe Armand, Michelle Fanale, Voravit Ratanatharathorn, John Kuruvilla,[...]. Lancet Oncol 2016
557
16

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
15

PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol 2008
15

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Philippe Armand, Andreas Engert, Anas Younes, Michelle Fanale, Armando Santoro, Pier Luigi Zinzani, John M Timmerman, Graham P Collins, Radhakrishnan Ramchandren, Jonathon B Cohen,[...]. J Clin Oncol 2018
285
14

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Lakshmi Nayak, Fabio M Iwamoto, Ann LaCasce, Srinivasan Mukundan, Margaretha G M Roemer, Bjoern Chapuy, Philippe Armand, Scott J Rodig, Margaret A Shipp. Blood 2017
207
14

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, Diva R Salomao, Hideto Tamura, Fumiya Hirano, Dallas B Flies, Patrick C Roche, Jun Lu, Gefeng Zhu, Koji Tamada,[...]. Nat Med 2002
13

Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Poonam K Panjwani, Vivek Charu, Monique DeLisser, Hernan Molina-Kirsch, Yasodha Natkunam, Shuchun Zhao. Hum Pathol 2018
58
22


Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
Konstantinos Georgiou, Longyun Chen, Mattias Berglund, Weicheng Ren, Noel F C C de Miranda, Susana Lisboa, Marco Fangazio, Shida Zhu, Yong Hou, Kui Wu,[...]. Blood 2016
110
13

Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Bjoern Chapuy, Margaretha G M Roemer, Chip Stewart, Yuxiang Tan, Ryan P Abo, Liye Zhang, Andrew J Dunford, David M Meredith, Aaron R Thorner, Ekaterina S Jordanova,[...]. Blood 2016
262
13

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Zijun Y Xu-Monette, Jianfeng Zhou, Ken H Young. Blood 2018
167
13

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.
Alina Nicolae, Stefania Pittaluga, Shahed Abdullah, Seth M Steinberg, Thu Anh Pham, Theresa Davies-Hill, Liqiang Xi, Mark Raffeld, Elaine S Jaffe. Blood 2015
139
13

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
12

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Xi-Wen Bi, Hua Wang, Wen-Wen Zhang, Jing-Hua Wang, Wen-Jian Liu, Zhong-Jun Xia, Hui-Qiang Huang, Wen-Qi Jiang, Yu-Jing Zhang, Liang Wang. J Hematol Oncol 2016
125
12

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Christopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G M Roemer, Edward C Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J Freeman, Donna Neuberg,[...]. Blood 2017
145
12

Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.
Takashi Oyama, Kazuhito Yamamoto, Naoko Asano, Aya Oshiro, Ritsuro Suzuki, Yoshitoyo Kagami, Yasuo Morishima, Kengo Takeuchi, Toshiyuki Izumo, Shigeo Mori,[...]. Clin Cancer Res 2007
298
12

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou,[...]. Oncotarget 2014
209
12

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
Yok-Lam Kwong, Thomas S Y Chan, Daryl Tan, Seok Jin Kim, Li-Mei Poon, Benjamin Mow, Pek-Lan Khong, Florence Loong, Rex Au-Yeung, Jabed Iqbal,[...]. Blood 2017
238
11

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand. Blood 2017
181
11

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Margaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, Christine J Pak, Sara Abdelrahman, Jing Ouyang, Stephanie Sasse, Anas Younes, Michelle Fanale, Armando Santoro,[...]. J Clin Oncol 2018
141
11

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Thomas Menter, Andrea Bodmer-Haecki, Stephan Dirnhofer, Alexandar Tzankov. Hum Pathol 2016
88
11

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Philippe Armand, Scott Rodig, Vladimir Melnichenko, Catherine Thieblemont, Kamal Bouabdallah, Gayane Tumyan, Muhit Özcan, Sergio Portino, Laura Fogliatto, Maria D Caballero,[...]. J Clin Oncol 2019
80
12

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Keisuke Kataoka, Hiroaki Miyoshi, Seiji Sakata, Akito Dobashi, Lucile Couronné, Yasunori Kogure, Yasuharu Sato, Kenji Nishida, Yuka Gion, Yuichi Shiraishi,[...]. Leukemia 2019
47
21

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
Philippe Armand, Arnon Nagler, Edie A Weller, Steven M Devine, David E Avigan, Yi-Bin Chen, Mark S Kaminski, H Kent Holland, Jane N Winter, James R Mason,[...]. J Clin Oncol 2013
351
9

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Wei Ding, Betsy R LaPlant, Timothy G Call, Sameer A Parikh, Jose F Leis, Rong He, Tait D Shanafelt, Sutapa Sinha, Jennifer Le-Rademacher, Andrew L Feldman,[...]. Blood 2017
201
9

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch,[...]. Lancet Haematol 2019
77
11

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
Christian Steidl, Tang Lee, Sohrab P Shah, Pedro Farinha, Guangming Han, Tarun Nayar, Allen Delaney, Steven J Jones, Javeed Iqbal, Dennis D Weisenburger,[...]. N Engl J Med 2010
845
9

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Alex F Herrera, Alison J Moskowitz, Nancy L Bartlett, Julie M Vose, Radhakrishnan Ramchandren, Tatyana A Feldman, Ann S LaCasce, Stephen M Ansell, Craig H Moskowitz, Keenan Fenton,[...]. Blood 2018
182
9

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
David D W Twa, Fong Chun Chan, Susana Ben-Neriah, Bruce W Woolcock, Anja Mottok, King L Tan, Graham W Slack, Jay Gunawardana, Raymond S Lim, Andrew W McPherson,[...]. Blood 2014
190
9

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Reid W Merryman, Philippe Armand, Kyle T Wright, Scott J Rodig. Blood Adv 2017
71
12

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Philippe Armand, Yi-Bin Chen, Robert A Redd, Robin M Joyce, Jad Bsat, Erin Jeter, Reid W Merryman, Kimberly C Coleman, Parastoo B Dahi, Yago Nieto,[...]. Blood 2019
55
16

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
James Godfrey, Sravya Tumuluru, Riyue Bao, Michael Leukam, Girish Venkataraman, John Phillip, Carrie Fitzpatrick, James McElherne, Brendan W MacNabb, Robert Orlowski,[...]. Blood 2019
45
20

Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients.
Takashi Oyama, Koichi Ichimura, Ritsuro Suzuki, Junji Suzumiya, Koichi Ohshima, Yasushi Yatabe, Takio Yokoi, Masaru Kojima, Yoshikazu Kamiya, Hirofumi Taji,[...]. Am J Surg Pathol 2003
258
9

Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Ayako Sakakibara, Kei Kohno, Ahmed E Eladl, Teerada Klaisuwan, Eri Ishikawa, Yuka Suzuki, Satoko Shimada, Masato Nakaguro, Yoshie Shimoyama, Taishi Takahara,[...]. Histopathology 2018
28
32

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.
Stefan D Dojcinov, Girish Venkataraman, Stefania Pittaluga, Iwona Wlodarska, Jeffrey A Schrager, Mark Raffeld, Robert K Hills, Elaine S Jaffe. Blood 2011
193
9

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda, Seiji Sakata, Misako Matsumoto, Seiji Nagano, Takuya Maeda, Yasunobu Nagata, Akira Kitanaka, Seiya Mizuno,[...]. Nature 2016
349
9

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
Michal Marzec, Qian Zhang, Ami Goradia, Puthiyaveettil N Raghunath, Xiaobin Liu, Michele Paessler, Hong Yi Wang, Maria Wysocka, Mangeng Cheng, Bruce A Ruggeri,[...]. Proc Natl Acad Sci U S A 2008
474
8

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
8

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
Radhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, Marek Trněný, Tatyana A Feldman, Hun Ju Lee, Mariano Provencio, Christian Sillaber, Jonathon B Cohen, Kerry J Savage,[...]. J Clin Oncol 2019
78
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.